NCT01414244

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

Randomized, Placebo-Controlled Trial of Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Tulane University · Academic / Other
• Sex: All
• Age: 18 Years – 72 Years
• Healthy volunteers: Not accepted

Summary

New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino acid in the body and the principal fuel for enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with increased intestinal permeability following an enteric infection.

Detailed description

In a double-blind trial, eligible adults with post-infectious IBS with increased intestinal permeability were randomly assigned to receive either glutamine (5 g three times daily) or placebo for eight weeks. The primary end point was the proportion of patients who had a reduction of ≥50 on the Irritable Bowel Severity Scoring System (IBS-SS).

Conditions

• Diarrhea-Predominant Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Glutamine	Drug

Timeline

• Start date: 2010-11-01
• Primary completion: 2015-12-30
• Completion: 2015-12-30
• First posted: 2011-08-11
• Last updated: 2017-08-09
• Results posted: 2017-08-09

Locations

1 site across 1 country: United States